Emory HIV/AIDS Clinical Trials Unit

埃默里艾滋病毒/艾滋病临床试验单位

• 批准号: 7340768
• 负责人: Jeffrey Lennox
• 金额: $ 325.3万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-01 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7340768
• 关键词: AIDS clinical trial group; AIDS/HIV problem; Accounting; Acquired Immunodeficiency Syndrome; Adult; African American; Agreement; Area; Caring; Cities; Clinic; Clinical Research; Clinical Trials; Communicable Diseases; Country; Doctor of Medicine; Epidemic; Faculty; Female; HIV; HIV prevention trials network; HIV vaccine; Hispanics; Leadership; Medical center; Microbicide Trials Network; Minority; Patients; Population; Principal Investigator; Reporting; Research; Scientist; Site; Testing; USA Georgia; United States; United States Department of Veterans Affairs; Universities; Vaccines; Veterans; Western Asia Georgia; Woman; Work; clinical research site; insight; men; metropolitan; microbicide

DESCRIPTION (provided by applicant): Through this application, NIAID-sponsored clinical research at Emory University will be integrated into the Emory HIV/AIDS Clinical Trials Unit (EHCTU). The EHCTU will perform clinical research trials through prior agreement with the AIDS Clinical Trials Group (ACTG) and the Microbicides Trials Network (MTN). In addition, the EHCTU has the scientific expertise and appropriate patient populations to make important contributions to the HIV Vaccine Trials Network (HVTN), the HIV Prevention Trials Network (HPTM) and the INSIGHT network. Emory scientists currently make important scientific and leadership contributions to each of these networks. Emory University is located in Atlanta, a city at the epicenter of the evolving HIV epidemic in the United States. Of the 101 metropolitan areas with a population greater than 500,000, Atlanta ranked 7th for AIDS reporting in 2003. Atlanta accounts for 67% of Georgia's African-American AIDS cases, 75% of Hispanic cases, and 56% of minority female cases. Emory faculty provides care for about6,000 HIV-infected men and over 1,000 infected women. The EHCTU will consist of an administrative core and three clinical research sites. Jeffrey Lennox, M.D. will be the Principal Investigator for the EHCTU and for the ACTG at Emory. Carlos del Rio, M.D. will be the Principal Investigator for the HPTN trials. The Ponce de Leon Center, where over 4,000 HIV-infected adults are in care, will be the research site for the ACTG and HPTN. Francis Priddy, M.D. will be the Principal Investigator for the HVTN and MTN trials. These trials will be done at the Hope Clinic of the Emory Vaccine Center, one of the leading HIV vaccine and microbicides testing sites in the United States. David Rimland, M.D. will be the Principal Investigator for the INSIGHT trials. These trials will be performed at the Atlanta Veterans Administration Medical Center, which has the largest population of HIV-infected veterans in the country. Dr's Lennox, del Rio, Priddy and Rimland are all faculty in the Division of Infectious Diseases, have an excellent working relationship and a demonstrated record of collaborative clinical research accomplishments. ADMINISTRATIVE COMPONENT:

描述（由申请人提供）： 通过这项申请，NIAID在埃默里大学赞助的临床研究将被整合到埃默里艾滋病毒/艾滋病临床试验单位（EHCTU）。EHCTU将通过与艾滋病临床试验组（ACTG）和杀微生物剂试验网络（MTN）的事先协议进行临床研究试验。此外，EHCTU拥有科学专业知识和适当的患者群体，可以为艾滋病毒疫苗试验网络（HVTN），艾滋病毒预防试验网络（HPTM）和INSIGHT网络做出重要贡献。埃默里大学的科学家目前为这些网络中的每一个做出了重要的科学和领导贡献。埃默里大学位于亚特兰大，这是美国艾滋病流行的中心城市。在101个人口超过50万的大都市地区中，亚特兰大在2003年艾滋病报告中排名第七。亚特兰大占格鲁吉亚非洲裔美国人艾滋病病例的67%，西班牙裔病例的75%，少数民族女性病例的56%。埃默里大学的教师为大约6,000名艾滋病感染者和1,000多名感染者提供护理。EHCTU将由一个行政核心和三个临床研究中心组成。Jeffrey伦诺克斯，医学博士将是埃默里大学EHCTU和ACTG的主要研究者。卡洛斯德尔里奥，医学博士将担任HPTN试验的主要研究者。庞塞德莱昂中心将成为ACTG和HPTN的研究地点，那里有4,000多名艾滋病毒感染者。医学博士弗朗西斯·普里迪将担任HVTN和MTN试验的主要研究者。这些试验将在埃默里疫苗中心的希望诊所进行，埃默里疫苗中心是美国领先的艾滋病毒疫苗和杀微生物剂试验场所之一。大卫里姆兰，医学博士将担任INSIGHT试验的主要研究者。这些试验将在亚特兰大退伍军人管理局医疗中心进行，该中心拥有全国最多的艾滋病毒感染退伍军人。博士的伦诺克斯，德尔里奥，普里迪和里姆兰都是传染病科的教师，有一个良好的工作关系和合作临床研究成果的证明记录。 行政部门：